Acumen Pharmaceuticals (ABOS)Officer sold ~$6.8K

~$6.8K

Approx. value · 2,090 sh @ $3.26

174K

Holds after · shares reported

Traded

Mar 6, 2026

Filed

Mar 11, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 5, 2026Insider · 5 peopleInsiders: 5 sales (~$41K)
2. Jan 6, 2026Insider · 5 peopleInsiders: 6 sales (~$62K)
3. Jan 7, 2026Insider · 6 peopleInsiders: 8 sales (~$119K)
4. Jan 8, 2026Insider · 5 peopleInsiders: 6 sales (~$113K)
5. Jan 9, 2026Insider · 2 peopleInsiders: 2 sales (~$32K)
6. Jan 12, 2026Insider · 2 peopleInsiders: 2 sales (~$24K)
7. Jan 21, 2026Insider · 5 peopleInsiders: 5 sales (~$34K)
8. Jan 22, 2026Insider · 5 peopleInsiders: 5 sales (~$13K)
9. Jan 23, 2026InsiderOfficer sold ~$11K of ABOS shares in the open market
10. Jan 26, 2026InsiderOfficer sold ~$45K of ABOS shares in the open market
11. Jan 28, 2026InsiderOfficer sold ~$8K of ABOS shares in the open market
12. Feb 27, 2026InsiderOfficer sold ~$28K of ABOS shares in the open market
13. Mar 6, 2026 · this disclosureInsiderOfficer sold ~$6.8K of ABOS shares in the open market

What came next

1. Mar 13, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
2. Mar 26, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
3. May 12, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
4. Jun 9, 2026InsiderDirector sold ~$14K of ABOS shares in the open market
5. Jun 15, 2026InsiderDirector sold ~$15K of ABOS shares in the open market
6. Jun 16, 2026InsiderDirector sold ~$30K of ABOS shares in the open market
7. Jun 17, 2026InsiderDirector sold ~$30K of ABOS shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Acumen Pharmaceuticals

OQRO holds no insider, Congress, fund or contract record for Acumen Pharmaceuticals dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABOS page.

Other recent filings by Derek M Meisner, Chief Legal Officer & Corp Sec

• SEC Form 4 at Acumen Pharmaceuticals (ABOS)Mar 4, 2026
• SEC Form 4 at Acumen Pharmaceuticals (ABOS)Jan 29, 2026
• SEC Form 4 at Acumen Pharmaceuticals (ABOS)Jan 29, 2026
• SEC Form 4 at Acumen Pharmaceuticals (ABOS)Jan 23, 2026
• SEC Form 4 at Acumen Pharmaceuticals (ABOS)Jan 23, 2026

The full history of Derek M Meisner, Chief Legal Officer & Corp Sec is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Acumen Pharmaceuticals

• SEC Form 4Jun 17, 2026
• SEC Form 4Jun 17, 2026
• SEC Form 4Jun 17, 2026
• SEC Form 4Jun 10, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 4Mar 4, 2026

Everything OQRO holds on this company is on its ABOS page.